Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1179-1926
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation ; volume:61 ; number:4 ; day:20 ; month:1 ; year:2022 ; pages:465-479 ; date:4.2022
Clinical pharmacokinetics ; 61, Heft 4 (20.1.2022), 465-479, 4.2022

Urheber
Angiolillo, Dominick J.
Prats, Jayne
Deliargyris, Efthymios N.
Schneider, David J.
Scheiman, James
Kimmelstiel, Carey
Steg, Ph. Gabriel
Alberts, Mark
Rosengart, Todd
Mehran, Roxana
Bhatt, Deepak L.
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s40262-021-01090-2
URN
urn:nbn:de:101:1-2022062118522126151345
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:30 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Angiolillo, Dominick J.
  • Prats, Jayne
  • Deliargyris, Efthymios N.
  • Schneider, David J.
  • Scheiman, James
  • Kimmelstiel, Carey
  • Steg, Ph. Gabriel
  • Alberts, Mark
  • Rosengart, Todd
  • Mehran, Roxana
  • Bhatt, Deepak L.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study

Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin

Population pharmacokinetic/pharmacodynamic analysis of lopinavir and ritonavir in subjects receiving the tablet formulation

Population pharmacokinetic/pharmacodynamic analysis of lopinavir and ritonavir in subjects receiving the tablet formulation

Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study

Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat

Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat

A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim

A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim

Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat

Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat

Pharmacokinetic/pharmacodynamic evaluation of gamithromycin against rabbit pasteurellosis

Pharmacokinetic/pharmacodynamic evaluation of gamithromycin against rabbit pasteurellosis

A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis

A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis

Optimal designs for composed models in pharmacokinetic-pharmacodynamic experiments

Optimal designs for composed models in pharmacokinetic-pharmacodynamic experiments

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria

Verbundene Objekte